These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12608105)

  • 1. Bristol-Myers cleans up its mess.
    Revell J
    Fortune; 2003 Feb; 147(3):136-8. PubMed ID: 12608105
    [No Abstract]   [Full Text] [Related]  

  • 2. Bristol-Myers Squibb drug information department services.
    Sylvan L; Palmer-Shevlin N
    Hosp Pharm; 1995 Jan; 30(1):38-9, 44. PubMed ID: 10139729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug firms set deal.
    Scott L
    Mod Healthc; 1995 May; 25(19):4. PubMed ID: 10142258
    [No Abstract]   [Full Text] [Related]  

  • 4. Facelift in a bottle.
    O'Reilly B
    Fortune; 2002 Jun; 145(13):101-2, 104. PubMed ID: 12096458
    [No Abstract]   [Full Text] [Related]  

  • 5. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 7. Merck's man in the hot seat.
    Simons J
    Fortune; 2004 Feb; 149(4):111-2, 114. PubMed ID: 14983668
    [No Abstract]   [Full Text] [Related]  

  • 8. Sugen's strategy: a signal for P&U purchase.
    Glaser V
    Nat Biotechnol; 1999 Aug; 17(8):745-6. PubMed ID: 10429230
    [No Abstract]   [Full Text] [Related]  

  • 9. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 10. Authorized generics.
    Glass G
    Nat Rev Drug Discov; 2005 Dec; 4(12):953-4. PubMed ID: 16370080
    [No Abstract]   [Full Text] [Related]  

  • 11. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 12. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 13. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
    Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
    Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can J & J keep the magic going?
    Taylor A
    Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959
    [No Abstract]   [Full Text] [Related]  

  • 15. Extensive consolidations continue in drug industry.
    Scott L
    Mod Healthc; 1994 Sep; 24(36):12. PubMed ID: 10136392
    [No Abstract]   [Full Text] [Related]  

  • 16. Keys to CRM success. How well are contract pharmaceutical companies doing in the CRM game?
    Kros JF; Molis J
    Mark Health Serv; 2004; 24(4):32-6. PubMed ID: 15612224
    [No Abstract]   [Full Text] [Related]  

  • 17. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 18. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 19. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
    James JS
    AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.